Improving Fertility Through Science

Investor Relations

Investor Relations

Corporate Profile

OvaScience is a life sciences company focused on the discovery, development and commercialization of new treatments for infertility. The Company’s patented technology is based on the discovery of egg precursor cells (EggPCSM), which are found in the ovaries. By applying proprietary technology to identify and purify EggPCs, AUGMENTSM aims to improve egg quality and increase the success of in vitro fertilization (IVF). OvaScience’s team of scientists, physicians and advisers includes recognized leaders in the field of reproductive medicine.

OVAS (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$15.03
Change (%) Stock is Down 0.47 (3.03%)
Volume124,422
Data as of 09/19/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent News

More »
DateTitle 
09/18/14OvaScience Appoints Jeffrey Young to Chief Financial Officer
- Reports Inducement Option Grant under NASDAQ Rule 5635(c)(4) - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 18, 2014-- OvaScienceSM (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today the appointment of Jeffrey Young to Chief Financial Officer. Mr. Young joins OvaScience from Transmedics, Inc., where he served as Chief Financial Officer and Treasurer, lea... 
Printer Friendly Version
09/18/14OvaScience CEO Michelle Dipp Named Outstanding Young Leader
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 18, 2014-- OvaScienceSM (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today Michelle Dipp, M.D, Ph.D., Chief Executive Officer at OvaScience, has received the Ten Outstanding Young Leaders (TOYL) Award from the Greater Boston Chamber of Commerce. “Michelle is an inspiring leader who has made an important impa... 
Printer Friendly Version
09/03/14OvaScience to Present at the Rodman & Renshaw/H.C. Wainwright Annual Global Investment Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 3, 2014-- OvaScience℠ (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today that Company management will present at the Rodman & Renshaw 16th Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., on Wednesday, September 10, 2014 at 10:25 am ET at the New York Palace Hotel. A li... 
Printer Friendly Version
08/07/14OvaScience Reports Second Quarter 2014 Financial Results
- AUGMENT℠ Treatment Available in Three International Regions; Company More than Halfway Toward Goal of 40 AUGMENT Cycles in 2014 - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 7, 2014-- OvaScienceSM (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, today reported second quarter 2014 financial results and highlighted recent accomplishments. “Our progress t... 
Printer Friendly Version

Upcoming Events

More »
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.